Physician profile
Ying Xu
NPI 1487692760
$8,278.77
in general payments reported to CMS, 2019-2025
21 companies · $874 in 2025
The $874 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $1,558 · 2021: $1,841 · 2022: $1,054 · 2023: $1,000 · 2024: $1,079 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,953.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,896.26 | 2019-2025 | Rybelsus, Ozempic, Tresiba |
| Astrazeneca Pharmaceuticals LP | $1,494.48 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amarin Pharma, INC. | $994.76 | 2019-2023 | |
| Glaxosmithkline, LLC. | $533.35 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $501.98 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $471.35 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $381.07 | 2019-2023 | |
| Abbott Laboratories | $345.63 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.57 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $303.01 | 2021-2025 | Livalo, Seglentis, Zoryve |
| Merck Sharp & Dohme LLC | $195.88 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.74 | 2020-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $149.08 | 2020-2023 | Xarelto |
| Amgen INC. | $138.90 | 2020-2025 | Otezla, Repatha, Repatha |
| Exact Sciences Corporation | $120.99 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $72.68 | 2021-2025 | |
| Pfizer INC. | $66.18 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $63.99 | 2024-2025 | Keveyis |
| Allergan, INC. | $15.68 | 2020 | |
| Dermira, INC. | $12.40 | 2020 | |
| Horizon Therapeutics Plc | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ying Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.